Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics

G. Ruiz de Garibay,B. Roch,P. Garrido Lopez,D. Isla,C. Aguado,A. Callejo Perez,R. Marse Fabregat,M. R. Garcia Campelo,A. Blasco Cordellat,J. M. Sanchez Torres,R. Bernabe Caro,O. J. Juan Vidal,J. De Castro Carpeno,F. F. Franco, I. Ramos Garcia,A. Gomez Rueda,E. Conde Gallego,S. Ponce Aix,L. Paz-Ares,J. Zugazagoitia

Annals of Oncology（2022）

Cited 0|Views7
No score
Abstract
Osimertinib has shown robust survival benefit in advanced EGFR-mutant NSCLC. However, ≈ 15% of these patients experience disease progression within 6 months of therapy, and there is a need to identify targetable resistance mechanisms.
More
Translated text
Key words
early resistance mechanisms,first-line,egfr-mutant
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined